Tredje AP fonden lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 31.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,140 shares of the company’s stock after selling 3,700 shares during the period. Tredje AP fonden’s holdings in IDEXX Laboratories were worth $1,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently made changes to their positions in IDXX. Koch Industries Inc. raised its stake in shares of IDEXX Laboratories by 44,533.1% during the second quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock valued at $1,391,000 after acquiring an additional 1,396,113 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of IDEXX Laboratories by 486.4% during the second quarter. Janus Henderson Group PLC now owns 1,131,902 shares of the company’s stock valued at $182,711,000 after acquiring an additional 938,888 shares in the last quarter. BlackRock Inc. raised its stake in shares of IDEXX Laboratories by 10.5% during the second quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock valued at $1,146,142,000 after acquiring an additional 673,347 shares in the last quarter. Old Mutual Global Investors UK Ltd. bought a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $83,723,000. Finally, Arrowstreet Capital Limited Partnership raised its stake in shares of IDEXX Laboratories by 42.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock valued at $211,567,000 after acquiring an additional 392,790 shares in the last quarter. 86.80% of the stock is owned by institutional investors and hedge funds.
Several analysts have recently weighed in on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research note on Monday, August 21st. Bank of America raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target for the company in a research note on Wednesday, August 23rd. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a research note on Tuesday, August 22nd. Finally, Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $173.67.
In related news, insider Giovani Twigge sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the business’s stock in a transaction that occurred on Friday, November 3rd. The stock was sold at an average price of $153.75, for a total transaction of $2,767,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,064,573 shares of the company’s stock, valued at approximately $163,678,098.75. The disclosure for this sale can be found here. Insiders sold 110,000 shares of company stock valued at $16,686,200 in the last three months. 2.77% of the stock is currently owned by insiders.
IDEXX Laboratories, Inc. (NASDAQ IDXX) opened at $160.57 on Friday. The company has a market cap of $13,954.12, a P/E ratio of 53.87, a P/E/G ratio of 2.42 and a beta of 0.42. IDEXX Laboratories, Inc. has a 12 month low of $113.92 and a 12 month high of $173.01. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48.
IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. The company had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.62 earnings per share. analysts forecast that IDEXX Laboratories, Inc. will post 3.24 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/12/09/tredje-ap-fonden-has-1-27-million-holdings-in-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.